Glenn Wilkins - Friday, July 18, 2025 Knight Therapeutics Inc. 09:43 AM EST - Knight Therapeutics Inc. : Announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by Health Canada. Knight Therapeutics Inc. shares T.GUD are trading unchanged at $6.21.